Full-Time

Category Management Capability Lead

Posted on 11/23/2025

Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

No salary listed

Madrid, Spain + 1 more

More locations: Welwyn Garden City, UK

In Person

Flex Location allows work from various places around the world for a defined period.

Category
Operations & Logistics (1)
Required Skills
Agile
Data Analysis
Requirements
  • You hold a university degree, preferably in business or a related discipline.
  • You have 10+ years of procurement experience in strategic sourcing, global category management, complex procurement contracting, and operational category efficiency projects.
  • You have significant experience in managing teams in a global, fluid and interactive environment, ideally in a matrix environment.
  • You are a strong advocate of agile ways of working, preferably with direct experience in agile leadership.
  • You have expertise in procurement end-to-end systems and processes.
  • You demonstrate curiosity, active listening and a willingness to experiment and test new ideas when appropriate, with the focus very much on continuous learning and improvement.
  • You are open-minded and inclusive, generously sharing ideas and knowledge, while being receptive to ideas and feedback from others.
  • You have experience in project management including change management and process improvement with direct experience in delivering complex business process / organizational change projects.
  • You are fluent in English to a Business level.
Responsibilities
  • You will work in a dynamic global environment where you will bring analytical thinking, planning, execution, and focus to the procurement sourcing and delivery capability area.
  • You will utilise your leadership expertise and your specialized knowledge and in-depth expertise in strategic sourcing, global category management and procurement overall, to drive collaboration with internal procurement and functional management to contribute and implement a best-in-class procurement delivery capability in your area.
  • You will be responsible for the end-to-end management and strategic direction of Category Strategies within Global Procurement, drive alignment with the overarching Procurement strategy, digital initiatives, and customer satisfaction, and ensure consistent application of procurement methodologies.
  • You will also contribute to continuous improvement projects and support both Procurement Delivery Chapters, by clearly defining what excellence looks like for global Category Management, establishing an integrated plan for establishing, implementing and enhancing global Category Management and applying a data driven approach to measure progress against this plan, while removing impediments and blockers, ensuring champion adoption, and enhancing overall procurement delivery performance.
  • You will collaborate with internal procurement (such as both Delivery Chapters, Customer Excellence, Business and Digital Solutions, Analytics, Contracting, Learning and Development, etc.) functional management and business stakeholders to build and implement a best in class procurement delivery capability ensuring balanced team resource utilisation, consistent application of procurement methodologies and contribution to continuous improvement projects.
  • You will work closely with Procurement Managers from both Delivery Chapters to establish and embed a global Category Management framework in Global Procurement.
  • You will further work with other Delivery team members, as a coach, project, or workstream lead to identify opportunities to develop and enhance existing Category Strategies considering Category Archetypes and business priorities, and provide capacity, expertise, and oversight to productivity and other customer oriented projects/solutions.
  • As a Capability Lead - Category Management, you will play a variety of roles according to your experience, knowledge, and general business requirements, including but not limited to:
  • You are a subject matter expert in global Category Management, evaluating project requests and business needs to develop and execute global Category Strategies and best practices in alignment with the Procurement strategy, digital initiatives and stakeholder / business needs.
  • You will own the end-to-end process for the Category Management Capability area, from strategic conception to end-user adoption, ensuring seamless integration and a consistent approach to Category Management and Strategic Sourcing within Global Procurement.
  • You develop content and automation, Category Management guidelines, best practices, training and communication materials that improve adoption, satisfaction, and overall efficiency of the Category Management Capability within Global Procurement.

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Simplify Jobs

Simplify's Take

What believers are saying

  • CT-388 targets double-digit share in obesity market alongside Novo Nordisk and Lilly.
  • PathAI $750M acquisition scales AI digital pathology globally by late 2026.
  • Elecsys pTau217 Alzheimer's blood test launches in CE markets from July 2026.

What critics are saying

  • Rituxan patent expiry lets Sandoz biosimilars slash 40% lymphoma share in 6-12 months.
  • Swiss franc 12% rise compresses US 55% revenues as hedges expire in 6-18 months.
  • US IRA forces 60-80% discounts on Herceptin, Avastin from 2028, cutting $4B cashflow.

What makes Roche unique

  • Roche integrates pharmaceuticals and diagnostics via 1991 PCR acquisition from Cetus.
  • 1990 Genentech majority stake pioneered oncology antibodies like Herceptin and Rituxan.
  • Personalized healthcare strategy couples diagnostics to targeted therapies since 2009 full acquisition.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.

INACTIVE